Spike glycoprotein S1 receptor-binding domain of SARS-CoV-2 Omicron variant (S1 RBD (Omicron))

The spike glycoprotein S1 receptor-binding domain (RBD) of the SARS-CoV-2 Omicron variant is a region within the S1 subunit of the viral spike protein responsible for binding to the host angiotensin-converting enzyme 2 (ACE2) receptor, thereby facilitating viral entry into target cells[1][2][3][4]. The Omicron variant's RBD contains an unusually high number of mutations compared to previous variants, resulting in altered antigenic structure, enhanced ability to evade neutralizing antibodies elicited by prior infection or vaccination, and a requirement for higher ACE2 density for efficient membrane fusion[3][4]. These changes contribute to Omicron's increased transmissibility, partial resistance to existing monoclonal antibodies, and continued importance as a focus for vaccines and therapeutics development[2][3][4]. It remains a major target for neutralizing antibodies, serologic biomarkers, and therapeutic drugs aiming to block viral entry.

Other names

SARS-CoV-2 spike protein receptor-binding domain (Omicron)Spike protein RBD (Omicron)S1 RBD (B.1.1.529)SARS-CoV-2 Omicron S1 RBD

Drugs/antibodies inhibit viral entry by blocking the RBD-ACE2 interaction Monoclonal antibodies neutralize by directly binding RBD and preventing receptor engagement Vaccines elicit antibodies targeting RBD to prevent infection